CureDuchenne and Avidity Biosciences Host Webinar on Pre-clinical Development of Novel Exon Skipping Therapies for Duchenne Muscular Dystrophy

Newport Beach, Calif. (November 5, 2018) – CureDuchenne, a global leader in research, patient care, and innovation in improving and extending the lives of those living with Duchenne muscular dystrophy (DMD), announced today it will host a webinar with Avidity Biosciences, a privately held biotech company pioneering a new class of precision medicines based upon antibody-oligonucleotide conjugates, to brief the Duchenne community about Avidity’s research in pre-clinical development of potential therapies to treat patients with Duchenne muscular dystrophy (DMD).

The Webinar will feature Debra Miller, founder and CEO, CureDuchenne and Arthur A. Levin, Ph.D., EVP of research and development, Avidity Biosciences.

The Webinar will be held on November 16, 2018 at 1:00 PT/4:00 ET.

To register, please click here:  https://bit.ly/2OryjSI.

The AOC™ technology being advanced by Avidity addresses a key issue of oligonucleotide therapeutics for Duchenne: namely, delivery of these powerful therapeutic agents for exon skipping to muscle, diaphragm and heart. Using antibody-mediated uptake in muscle cells, AOCs increase the activity of splice skipping oligonucleotides dramatically (a 100-fold increase in potency in the MDX mouse model), which should allow for reduced dose levels and reduced dosing frequency. This ground-breaking science provides a great opportunity to address Duchenne muscular dystrophy, and other muscle diseases.

About Avidity Biosciences

Avidity Biosciences is a privately held biotech company pioneering Antibody Oligonucleotide Conjugates (AOC™), which combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide-based therapeutics to overcome barriers to the delivery of oligonucleotides and target genetic drivers of disease. Avidity is advancing a pipeline of therapeutic programs focused on rare muscle disorders and other serious diseases. Avidity has raised $30 million in venture financing from a top-tier group of sophisticated healthcare investors. More information about Avidity can be found on the company’s website at www.aviditybio.com.

About CureDuchenne

CureDuchenne is the nation’s leading nonprofit organization dedicated to finding a cure for Duchenne, the most common and lethal form of muscular dystrophy. As the leading genetic killer of young boys, Duchenne affects more than 300,000 boys living today. CureDuchenne has garnered international attention for its efforts to raise funds and awareness for Duchenne through venture philanthropy. For more information on how to help raise awareness and funds needed for research, please visit www.cureduchenne.org.